Citi analyst Jason Cassorla raised the firm’s price target on HCA Healthcare to $324 from $293 and keeps a Buy rating on the shares. The company reported Q1 results with strong volume momentum, favorable acuity/payor mix trends, and continued expense management driving EBITDA upside, the analyst tells investors in a research note. The firm says favorable commercial rates, continued labor improvement, and share-taking could potentially buoy HCA’s growth ahead of the long-term 4%-6% target for the foreseeable future.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HCA:
